Sarepta Initiates Trial to Mitigate ELEVIDYS Liver Injury Risk
Event summary
- Sarepta has begun screening and enrollment for ENDEAVOR Cohort 8, a Phase 1b study evaluating ELEVIDYS gene therapy.
- The cohort will assess prophylactic sirolimus treatment to reduce acute liver injury (ALI) risk in non-ambulatory Duchenne patients.
- Approximately 25 U.S. participants are being enrolled, receiving 14 days of peri-infusion sirolimus followed by 12 weeks of continued dosing.
- The trial will measure incidence of ALI and dystrophin expression at 12 weeks as primary endpoints.
The big picture
Sarepta's ongoing efforts to refine ELEVIDYS’ safety profile are crucial given the therapy's boxed warning for acute liver injury. This cohort represents a targeted attempt to expand the eligible patient population – non-ambulatory individuals – who have been largely excluded due to heightened risk. The trial's outcome will significantly influence investor confidence and the company's ability to capitalize on the growing gene therapy market for Duchenne muscular dystrophy.
What we're watching
- Safety Profile
- The success of this cohort hinges on whether sirolimus effectively reduces ALI without compromising ELEVIDYS efficacy or introducing new safety concerns, which will be critical for broader adoption.
- Regulatory Approval
- The FDA's acceptance of this enhanced safety protocol as a pathway to broader ELEVIDYS use in non-ambulatory patients will dictate the therapy's long-term commercial viability.
- Patient Adoption
- The willingness of physicians and patients to adopt a more complex treatment regimen involving sirolimus will be a key factor in ELEVIDYS’s uptake, especially given existing safety concerns.
Related topics